¡¾ÕªÒª¡¿ Ä¿µÄ ̽ÌÖÃÚÄòϵͳ¸ÐȾ²úø³¦¸Ë¾ú¿Æϸ¾úµÄ·ÖÀëÂʼ°ÄÍÒ©ÐÔ£¬ÎªÁÙ´²ÕïÖÎÌṩ°ïÖú¡£·½·¨³£¹æÅàÑø·ÖÀëϸ¾ú£¬Ó¦ÓÃVITEK΢ÉúÎï×Ô¶¯·ÖÎöÒÇ»òAPI¼ø¶¨ÏµÍ³¼ø¶¨¾úÖÖ;ESBLs¼ì²â²ÉÓÃ˫ֽƬȷÈÏ·¨:AmpCø¼ì²â²ÉÓÃÈýάÊÔÑéÈ·ÈÏ·¨;Ò©ÃôÊÔÑé²ÉÓÃK-BֽƬÀ©É¢·¨ºÍÈâÌÀ¶¨Á¿Ï¡ÊÍ·¨£¬°´NCCLS¹æ¶¨µÄ±ê×¼½øÐС£½á¹û 106Ö곦¸Ë¾ú¿Æϸ¾úÖд󳦸˾úÕ¼¾úȺµÄ77.4%£¬²úESBLsºÍAmpCøµÄÑôÐÔÂÊΪ26.8%ºÍ6.1%¡£²úø¾ú¶ÔÌ©ÄÜÈ«²¿Ãô¸Ð£¬¶Ô¶¡°·¿¨ÄÇùËصÄÄÍÒ©ÂÊ×î¸ßΪ25.0%£¬¶ÔÂí˹ƽµÄÄÍÒ©ÂÊ×îµÍΪ37.5%¡£²úø¾ú¶ÔÌ©ÄܵÄMIC 90 ¡Ü2mg/L£¬¶ÔÂí˹ƽ¡¢ÊæÆÕÉîµÄMIC 90 ¾ù¡Ý64mg/L¡£½áÂÛ Óɳ¦¸Ë¾ú¿Æϸ¾úÒýÆðµÄÃÚÄòϵͳ¸ÐȾÖ÷ÒªÒԴ󳦸˾úΪÖ÷£¬Æä²úESBLs¸ß´ï26.8%¡£¶Ô²úø¾úÒýÆðµÄ¸ÐȾӦÊ×Ñ¡Ì©ÄÜÖÎÁÆ¡£
¹Ø¼ü´Ê ÃÚÄòϵͳ ³¦¸Ë¾ú¿Æϸ¾ú ¦Â-ÄÚõ£°·Ã¸È¾É«ÌåBUSH-¢ñÐÍø ¿¹¾úÒ©Îï ÄÍÒ©ÐÔ
Analysis of isolating rates and drug resistance
to zymogenic enterobacteriaceae bacteria in urinary system
Feng Haixiang£¬Xu Xiuli
Department of Laboratory£¬the First Hospital of Yulin City£¬Shaanxi718000.
¡¾Abstract¡¿ Objective To understand the zymogenic rates and drug resistance of enterobacteriaceae bacteria in urinary system infection in order to provide assistance to clinical diagnosis and therapy.Methods All isolates were identified by Vitek microbe automatic instrument and API indentifying system.ESBLs was detected by double disk syn¡¥ergy test.AmpC was detected by three dimensional test.Drug sensitive tests used K-B paper disk diffusion and broth quatative dilution method in accordance with NCCLS standards.Results The isolated rates of E.coliwere77.4%in106strains enterobacteriaceae bacteria.The positive rates of ESBLs and AmpC were26.8%and6.1%.The zymo¡¥genic bacteria were all sensitive to imipenem£¬to amikacin was below25.0%£¬to cefepime was high37.5%.The zymo¡¥genic bacteriato ImipenemMIC 90 are¡Ü2mg/L£¬to sulperozone and cefepime are¡Ý64mg/L.Conclusion E.coli are main bacteria in urinary system infection£¬its ESBLs are26.8%.Imipenem are best choise for treatment to zymogenic bacteria.
Key words urinary system enterobacteriacea bacteria ESBLs AmpC antimicrobial agents drug resis¡¥tance
ÃÚÄòϵ¸ÐȾ£¨UTI£©ÊÇÁÙ´²³£¼ûµÄ¸ÐȾÐÔ¼²²¡£¬ÓÈÒÔ³¦¸Ë¾ú¿Æϸ¾ú¸ÐȾΪÖ÷£¬ÓÉÓÚÁÙ´²¹ã·ºµÄ²»ºÏÀíÓ¦Óÿ¹¾úÒ©Îʹ³¦¸Ë¾ú¿Æϸ¾ú²ú³¬¹ãÆצÂ-ÄÚõ£°·Ã¸£¨ESBLs£©ºÍȾɫÌåBUSH-¢ñÐÍø£¨AmpCø£©ÈÕÇ÷ÑÏÖØ£¬¸øÁÙ´²ÓÃÒ©ÖÎÁÆ´øÀ´ÁËÀ§ÄÑ¡£ÎªÁ˽âUTIµÄ³¦¸Ë¾úϸ¾úµÄ²úøÂʼ°ÄÍÒ©×´¿ö£¬ÎÒÃǶÔÒýÆðUTIµÄ106Ö곦¸Ë¾ú¿Æϸ¾ú½øÐÐÁ˾úȺ·ÖÎöºÍAmpCø¼ì²â¼°Ò©ÃôÊÔÑ飬ΪÁÙ´²ºÏÀíÓ¦Óÿ¹¾úÒ©ÎïÌṩ°ïÖú¡£
1 ²ÄÁÏ
1.1 ¾úÖêÀ´Ô´ ´ÓÁÙ´²UTIµÄÖжÎÄò±ê±¾Öй²·ÖÀ볦¸Ë¾ú¿Æϸ¾ú5Àà106Öê¾ú¡£
1.2 ±ê±¾ÖʿؾúÖê ´ó³¦¸Ë¾úATCC25922¡¢½ð»ÆÉ«ÆÏÌÑÇò¾úATCC25923¡¢ÍÂ̼ٵ¥°û¾úATCC27853¡¢·ÎÑ׿ËÀײ®¾úATCC700603£¬¹ºÓÚÎÀÉú²¿ÁÙ´²¼ìÑéÖÐÐÄ¡£
1.3 ÅàÑø»ù Mueller-HinfenÇíÖ¬¹ºÓÚ·¨¹úÉúÎï÷Àï°£¹«Ë¾£¬ÓªÑøÇíÖ¬¹ºÓÚÉϺ£ÒÁ»ªÒ½Ñ§¿Æ¼¼ÓÐÏÞ¹«Ë¾¡£
1.4 ¿¹ÉúËØƬ °±ÜÐÇàùËØ£¨AMP£©¡¢¶¡°·¿¨ÄÇùËØ£¨AMK£©¡¢ßßÀÎ÷ÁÖ/Ëûßò°Í̹£¨PIT£©¡¢Í·æßßòßø£¨CFZ£©¡¢Î÷Á¦ÐÀ£¨CFX£©¡¢»·±ûɳÐÇ£¨CIP£©¡¢Í·æßàçë¿£¨CTX£©¡¢°±ÇúÄÏ£¨ATM£©¡¢ÊæÆÕÉCPZ£©¡¢Ì©ÄÜ£¨IMP£©¡¢Âí˹ƽ£¨FEP£©¡¢Í·æßÎ÷¶¡£¨FOX£©¡¢Í·æßËûà¤/¿ËÀάËᣨCAZL£©¡¢Í·æßàçë¿/¿ËÀάËᣨCTXL£©£¬¹ºÓÚÉÂÎ÷Öб±¹«Ë¾£¬ÓÉÃÀ¹úB.D¹«Ë¾Éú²ú¡£Âí˹ƽ¹ºÓÚÖÐÃÀÉϺ£Ê©¹ó±¦ÖÆÒ©ÓÐÏÞ¹«Ë¾£¬ÅúºÅ:48488¡£ÊæÆÕÉÓÚÖйú´óÁ¬»ÔÈðÖÆÒ©ÓÐÏÞ¹«Ë¾£¬ÅúºÅ:15839025¡£Ì©ÄܹºÓÚº¼ÖÝĬɳ¶«ÖÆÒ©ÓÐÏÞ¹«Ë¾£¬ÅúºÅ:02525¡£
1.5 ÒÇÆ÷ VITEKÈ«×Ô¶¯Ï¸¾ú¼ø¶¨·ÖÎöÒǺÍAPI¼ø¶¨ÏµÍ³¹ºÓÚ·¨¹úÉúÎï÷Àï°£¹«Ë¾¡£
2 ·½·¨
2.1 ϸ¾ú¼ø¶¨ °´³£¹æ·½·¨·ÖÀëÅàÑøϸ¾ú£¬»ñ´¿ÅàÑøºó·´Ó¦ÓÃAPI¼ø¶¨ÏµÍ³¼ø¶¨µ½ÖÖ¡£
2.2 ESBLsøµÄ¼ì²â °´ÕÕNCCLSÍƼöµÄ±íÐÍÈ·ÈÏ·¨£Û1£Ý ¡£
2.3 AmpCøµÄ¼ì²â ²ÉÓÃÈýάÊÔÑéÈ·ÈÏ·¨ £Û2£Ý¡£
2.4 Ò©ÃôÊÔÑé ³£¹æÒ©ÃôÊÔÑé²ÉÓÃK-BֽƬÀ©É¢·¨²â¶¨¡£×îÒÖ¾úŨ¶È£¨MIC£©²â¶¨²ÉÓÃÈâÌÀ¶¨Á¿Ï¡ÊÍ·¨£¬Ñϸñ°´ÕÕNCCLS¹æ¶¨µÄ±ê×¼½øÐС£
3 ½á¹û
3.1 ³¦¸Ë¾ú¿Æϸ¾úµÄ·Ö²¼¼°Æä²úøÂÊ 106Ö곦¸Ë¾ú¿Æϸ¾úµÄ·Ö²¼¼°²úøÂʼû±í1¡£
±í1³¦¸Ë¾ú¿ÆµÄ·Ö²¼¼°Æä²úøÂÊ
±í2 106Ö곦¸Ë¾úµÄÄÍÒ©ÂÊ
±í3²úø¾úµÄÄÍÒ©ÂÊ
±í4 Âí˹ƽ¡¢ÊæÆÕÉ̩ÄܶÔ106Ö곦¸Ë¾ú¿Æϸ¾úµÄÌåÍ⿹¾ú»îÐÔ
3.2 ³¦¸Ë¾ú¿Æϸ¾úµÄÄÍÒ©ÂÊ 106Ö곦¸Ë¾úµÄÄÍÒ©Âʼû±í2;²úø¾úµÄÄÍÒ©Âʼû±í3;Âí˹ƽ¡¢ÊæÆÕÉ̩ÄÜ¡¢¶Ô106Ö곦¸Ë¾úµÄÌåÍ⿹¾ú»îÐÔ¼û±í4;3ÖÖ¿¹¾úÒ©Îï¶Ô²úø¾úµÄÌåÍ⿹¾ú»îÐÔ¼û±í5¡£
4 ÌÖÂÛ
UTIÖд󳦸˾úµÄ·ÖÀëÂÊΪ77.4%£¬ËµÃ÷´ó³¦°£Ï£¾úÊÇÒýÆðUTIµÄÖ÷ÒªÖ²¡¾ú¡£´ó³¦°£Ï£¾ú¶Ô°±ÜÐÇàùËصÄÄÍÒ©Âʸߴï95.1%£¬ÁÙ´²²»ÒËÑ¡ÓÃ;¶Ô»·±ûɳÐǵÄÄÍÒ©ÂÊ´ï75.6%£¬ÓëÍõöεȱ¨µÀµÄÒ»Ö £Û3£Ý £¬ÁÙ´²²»Ò˽«»·±ûÐÇɳ×÷Ϊ¾ÑéÓÃÒ©¡£²úESBLsÊdz¦¸Ë¾ú³£¼ûµÄÄÍÒ©»úÖÆ£¬²úESBLsøµÄ´ó³¦¸Ë¾úÕ¼26.8%£¬Óë¹úÄÚÓеĵØÇø±¨µÀµÄÏà²îºÜ´ó £Û4£Ý £¬Õâ¿ÉÄÜÓëµØÇø¼äµÄ¾úȺºÍÁÙ´²ÓÃÒ©²îÒìÐÔÏà¹Ø¡£²úø¾ú¶ÔÊæÆÕÉîµÄÄÍÒ©Âʸߴï52.0%£¬ÕâÓëÁÙ´²¸ÃÒ©ÎïÓ¦ÓÃƵÂʼ°ÓÃÒ©·½Ê½µÈÏà¹Ø£¬¹ÊÁÙ´²Ó¦¸ù¾ÝÒ©ÃôÊÔÑé½á¹û¼°¸öÌåÇé¿öÇ¡µ±Ê¹ÓÃÊæÆÕÉî¡£²úAmpCøµÄ³¦¸Ë¾ú¿Æϸ¾úÖ÷ÒªÊǴ󳦸˾úºÍ·ÎÑ׿ËÀײ®¾ú£¬¶ÔÂí˹ƽµÄÄÍÒ©ÂÊ´ï50.0%£¬¶Ô»·±ûɳÐÇÈ«²¿ÄÍÒ©£¬¶ø¶ÔÌ©ÄÜÈ«²¿Ãô¸Ð¡£¹Ê¶Ô²úAmpCøµÄ³¦¸Ë¾ú²»ÒËÑ¡ÓõÚËÄ´úÍ·æß¾úËؼ°»·±ûɳÐÇÖÎÁÆ£¬Ó¦Ê×Ñ¡Ì©ÄÜÖÎÁÆ¡£
±í5 3ÖÖ¿¹¾úÒ©Îï¶Ô²úøµÄÌåÍ⿹¾ú»îÐÔ
Ì©ÄܶÔ106Ö곦¸Ë¾úµÄÌåÍ⿹¾ú»îÐÔ×îºÃ£¬Ãô¸ÐÂÊΪ100%£¬´ÎΪÂí˹ƽ£¬²úø¾ú¶ÔÌ©ÄܵÄMIC 90 ¾ùÔÚ2mg/LÒÔÏ£¬¶ø¶ÔÂí˹ƽ¡¢ÊæÆÕÉîµÄMCI 90 ¾ù´óÓÚ»òµÈÓÚ64mg/L£¬¹Ê´ÓÌåÍ⿹¾ú»îÐÔÀ´¿´£¬Ì©ÄÜÈÔÊÇÖÎÁƲúø¾úµÄÊ×Ñ¡¿¹¾úÒ©Îï¡£
×÷Õߣº·ëº£Ïè ÐìÐÞÀñ ×÷Õßµ¥Î»:718000ÉÂÎ÷Ê¡ÓÜÁÖÊеÚÒ»Ò½Ôº¼ìÑé¿Æ 710032µÚËľüÒ½´óѧÎ÷¾©Ò½Ôº¼ìÑé¿Æ
²Î¿¼ÎÄÏ×
1 National Committee for Clinical Laboratory Standards.Performance stan¡¥dards for antimicrobial susceptibility testing£¬the ninth information.Sa¡¥tandard M100-59Pennsylranis:NCCLS£¬1999£¬87-98.
2 Coudron PE£¬Moland ES£¬Thomson KS.Occurrence and defection of Am¡¥pC beta lactamases among Escherichia coli£¬Klebsiella pneumoniae£¬and proteus mirabilis isolates at a veterans medical center.J Clin Microbial£¬2000£¬38:1791-1796.
3 ÓÚöΣ¬ÕÔ±¦Õ䣬Ñî¾´·¼£¬µÈ.ÃÚÄòϵ¸ÐȾ²¡Ô¾ú¾úȺ¼°ÄÍÒ©ÐÔ±äǨ.ÖлªÒ½Ôº¸ÐȾѧÔÓÖ¾£¬2002£¬12£¨11£©:861-862.
4 л¹úÇ¿£¬Íõ´ºÐ£¬Ê¢Ô£·¼£¬µÈ.ÃÚÄòϵ´ó³¦°£Ï£¾ú¸ÐȾÄÍÒ©ÐÔ¼°Æä²ú³¬¹ãÆצÂ-ÄÚõ£°·Ã¸·ÖÎö.ÖлªÒ½Ôº¸ÐȾѧÔÓÖ¾£¬2002£¬12£¨12£©:950-951.
ÉÏһƪ£º¸ÎÓ²»¯²¢·¢¸¹Ä¤Ñ×»ò°ÜѪ֢²¡Ô¾úÓëÒ©Ãô·ÖÎö
ÏÂһƪ£º²»Í¬³§¼Òö×ÊÔ¼Á¶Ôϸ¾úÄÚ¶¾ËØÏÞÁ¿¼ì²éµÄÓ°Ïì³õ̽